

**Date:** December 11, 2025

To,  
Sr. General Manager  
Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

**BSE Scrip Code: 544319**

To,  
Sr. General Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**NSE Symbol: SENORES**

Dear Sir/Madam,

**Sub.: Media Release – “Senores Pharmaceuticals, Inc. announces the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg which will be marketed by Dr. Reddy’s Laboratories Inc. in the US market”**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of Media Release being issued by the Company on the captioned subject.

The same is also being uploaded on the website of the Company at [www.senorespharma.com](http://www.senorespharma.com).

This is for information and records.

Thanking you.

**For Senores Pharmaceuticals Limited**

**Vinay Kumar Mishra**  
Company Secretary and Compliance Officer  
ICSI Membership No.: F11464

**Encl.:** As mentioned above

**Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,  
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: [info@senorespharma.com](mailto:info@senorespharma.com)

W: [www.senorespharma.com](http://www.senorespharma.com) | CIN No.: L24290GJ2017PLC100263

**MEDIA RELEASE**

**Senores Pharmaceuticals, Inc. announces the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg which will be marketed by Dr. Reddy's Laboratories Inc. in the US market**

**Atlanta, USA / Ahmedabad, India, December 11, 2025** – Senores Pharmaceuticals, Inc. today announced the launch of Deferiprone Tablets USP, 500 mg & 1000 mg, which is bioequivalent and therapeutically equivalent to Ferriprox Tablets of Chiesi USA, Inc. in the U.S. market. The product will be marketed by Dr. Reddy's Laboratories Inc.

“We are pleased to advance our growth with the launch of a limited-competition product. This aligns with our strategic focus on identifying and entering a niche, under-penetrated generic formulations with an opportunity to serve the unmet needs in healthcare” stated Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited.

Deferiprone Tablets, 500 mg & 1000 mg brand and generic products, had U.S. sales of approximately \$70 million MAT for the twelve months ending in October 2025 according to symphony.

**About Senores Pharmaceuticals Limited:**

Senores Pharmaceuticals Limited (together with its subsidiaries “**Senores**”) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio includes 46 ANDAs and 133 strengths along with a pipeline of 22 ANDAs and 52 strengths In the CMO/CDMO vertical 8 ANDAs and 24 products permitted for distribution in the USA along with a pipeline of 16 ANDAs and 57 strengths. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets, catering to more than 40 countries. The company currently has approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 394 product registrations and 824 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (“**API**”).

Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA, TAA & BAA compliant for controlled substances and government supplies & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

**Safe Harbor Statement:**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

**For more information, please contact:**

---

**Company: Senores Pharmaceuticals Limited****CIN: L24290GJ2017PLC100263****Mr. Deval Shah**Email: [investors@senorespharma.com](mailto:investors@senorespharma.com)For updates and specific queries,  
please visit[www.senorespharma.com](http://www.senorespharma.com)**Investor Relations: Strategic Growth Advisors****CIN: U74140MH2010PTC204285****Mr. Sagar Shroff / Mr. Tanay Shah**

M: +91 98205 19303 / +91 98333 91899

E-mail: [sagar.shroff@sgapl.net](mailto:sagar.shroff@sgapl.net) /  
[tanay.shah@sgapl.net](mailto:tanay.shah@sgapl.net)For updates and specific queries, please visit  
[www.sgapl.net](http://www.sgapl.net)